Prevention of Acute Cholecystitis With ETGBD
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Feb 28, 2024
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new method called endoscopic transpapillary gallbladder drainage (ETGBD) to see if it can help prevent a serious condition known as acute cholecystitis, which is inflammation of the gallbladder. The researchers believe that using a specific type of stent (a small tube that helps keep the duct open) during this procedure may be more effective for patients whose gallbladder ducts connect lower in the bile duct. By comparing the rates of complications and the need for additional procedures, they hope to find out if this approach truly offers benefits.
To be eligible for the trial, participants must be adults aged 19 or older and need to have certain imaging tests confirming the position of their gallbladder ducts. They should also be willing to give informed consent to join the study. However, individuals who have had previous drainage procedures, certain gastrointestinal issues, or other serious conditions like acute cholecystitis or pancreatitis won't be able to participate. If you join the trial, you can expect to undergo some tests and procedures related to your condition, all while contributing to important research that could improve treatment options for others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adults 19 years of age or older
- • 2. Patients requiring endoscopic retrograde cholangiography and drainage for therapeutic purposes.
- • 3. Patients with imaging (CT, Cholangiogram) confirmed confluence of the cystic duct with the distal third of the common bile duct.
- • 4. Patients who have voluntary informed consent to participate in the study.
- Exclusion Criteria:
- • Patients who have undergone percutaneous/surgical bile duct or gallbladder drainage prior to study enrollment.
- • Patients with anatomic deformity of the upper gastrointestinal tract after gastric or hepatobiliary surgery
- • Patients with concomitant gastric/duodenal obstruction
- • Patients with confirmed or suspected cystic duct obstruction on imaging studies
- • Patients with acute cholecystitis, acute pancreatitis
- • Patients who underwent cholecystectomy
- • Patients with a life expectancy of less than 3 months
- • Patients who are otherwise unable to undergo endoscopic retrograde cholangiopancreatography
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Woo Hyun Paik, MD., PhD.
Study Director
Seoul National University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported